Hepatitis C is a virus that causes liver inflammation. If not treated effectively it can lead to cirrhosis, liver failure, and even death. A new study tested whether a medication regimen directly targeting the virus could reduce viral levels in the blood for a group of patients who have characteristics associated with poor response to other treatments. Catherine Dolf explains in this week’s JAMA Report.

Source: Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics